Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albipagrastim alfa
- Development stage
- Unknown
- Lead developer
- Mabwell
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Albipagrastim alfa (QLC2519) is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) fusion protein developed by Qilu Pharmaceutical. It is composed of a modified G-CSF molecule fused to the C-terminal of human serum albumin (HSA). This modification is designed to maintain high biological activity while reducing the affinity for the G-CSF receptor, which inhibits receptor-mediated clearance (RMC) and significantly extends the drug's half-life compared to filgrastim. Albipagrastim alfa is indicated for the prevention of chemotherapy-induced neutropenia (CIN) and febrile neutropenia in patients with non-myeloid malignancies. It was approved by the China National Medical Products Administration (NMPA) in 2023 and is being further evaluated in pediatric populations with solid tumors, including sarcoma.
- Brand names
- Mai Li ShengMalisheng
- Other names
- albipagrastim alfAlbipagrastim alfa
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on albipagrastim alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albipagrastim alfa.